The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 16, 2023

Filed:

May. 22, 2020
Applicant:

Gc Cell Corporation, Gyeonggi-do, KR;

Inventors:

Jong Seo Lee, Gyeonggi-do, KR;

Kyu Tae Kim, Gyeonggi-do, KR;

Young Ha Lee, Seoul, KR;

In Sik Hwang, Incheon, KR;

Bong Kook Ko, Seoul, KR;

Eunji Choi, Yongin-si, KR;

You-Sun Kim, Yongin-si, KR;

Jeongmin Kim, Yongin-si, KR;

Miyoung Jung, Yongin-si, KR;

Hoyong Lim, Yongin-si, KR;

Sungyoo Cho, Yongin-si, KR;

Assignee:

GC Cell Corporation, Gyeonggi-do, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/32 (2006.01); C07K 14/705 (2006.01); A61P 35/00 (2006.01); A61K 38/17 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 16/32 (2013.01); A61K 38/177 (2013.01); A61P 35/00 (2018.01); C07K 14/705 (2013.01); C12N 5/0646 (2013.01); C07K 2317/565 (2013.01);
Abstract

The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.


Find Patent Forward Citations

Loading…